Pharvaris (PHVS) Cash from Restructuring (2021 - 2022)
Pharvaris (PHVS) posted Cash from Restructuring of -$115903.2 for Q4 2022, down 12315.94% on a QoQ basis from $948.79 in Q3 2022, and up 55.72% year-over-year from -$74430.1 in Q4 2021.
Pharvaris (PHVS) Cash from Restructuring (2021 - 2022) Analysis & Trends
Pharvaris' Cash from Restructuring history runs 2 years deep, the most recent figure standing at -$115903.2 for Q4 2022.
- Quarterly Cash from Restructuring rose 55.72% year-over-year to -$115903.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$376709.8 (changed N/A YoY) and the FY2025 annual result came in at -$12.3 million, down 2023.99% from the prior year.
- Cash from Restructuring was -$115903.2 for Q4 2022 at Pharvaris, down from $948.79 in the prior quarter.
- Across five years, Cash from Restructuring topped out at $948.79 in Q3 2022 and bottomed at -$261755.4 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -115,903.16 |
| Sep 30, 2022 | 948.79 |
| Dec 31, 2021 | -261,755.43 |